宜明昂科-B：年度业绩公告截至2024年12月31日止年度及建议变更所得款项用途

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.1541 202412 31 202412312023 20238 24 IMM01SIRP-Fc 20236IMM01(MDS)II2024123126.0(95%CI23.5–28.3)51(ORR)64.7%33.3%(CR)15.7%(mCR+HI)3.9% HI11.8% mCR2024II(ASCO)(PFS)2025 20235IMM01–(CMML)II2024123121.0(95%CI19.3–23.3)22(ORR)72.7%27.3% CR13.6% mCR4.5% HI27.3% mCR2024II(ESMO)PFS2025 202312IMM01PD-1(R/R)(cHL)II20241231338CR15(PR)ORR69.7%CRR24.2%IIASCOESMO2024(BOC)Best ofASCO®(BOC/BOA) 20244IMM01PD-(L) 1cHLIII20247 20245IMM01(HR-MDS)III(IND) 20246IMM01CMMLIIIIND202411 20253IMM01IMM2510IND IMM2510α(VEGFPD-L1) 20239IMM2510 I33II(RP2D)IMM2510 IPRSD15% 202311IMM2510Ib/II20241231Ib/II7420241231107I33 202310IMM2510IMM27MINDIMM2510–002IMM2510IMM27MR/RIb/II2024720247 IMM2510–003IMM2510NSCLCIb/II2024122025 IMM27M(CTLA-4 ADCC) IMM27M IIMM27M20241231PR IRP2D20249(HR+)HER2IMM27M IMM0306α(CD47CD20) IMM0306R/R(FL)(MZL)Ib202412311.6 mg/kg2.0 mg/kg11Ib113CRFL7PR 5FL2MZLORRCRR90.9%27.3%1.6 mg/kgIMM030620(RP2D)R/R FLMZL 20243IIa2024123136R/R FL2025 IMM2520 (CD47PD-L1) 2024123126IMM2520PR10%SD IMM0306α(CD47CD20) 202410(SLE)II720252SLE202412(NMOSD)II320252NMOSD202412(LN) IIIND(FDA)IND2025SLEIND IMM01SIRPα-FcIMM01INDIMM72/IMC-003ActRIIAIND20256INDIMM7220/IMC-010 (GLP-1 x ActRIIA 202481Axion Bio, Inc.Instil Bio, Inc. (TIL US)SynBioTx Inc.InstilPD-L1xVEGFIMM2510αCTLA-4(ADCC+) IMM27M5021 2024123115 2024123174.1202312310.473.7Axion Bio, Inc. 20231231291.910.6%20241231322.8(i)CMC43.6IMM2510IMM0306CDMO(ii)20247.418.3(i)CRO4.0(ii)14.320241231 2015Drug-by-Design11 (1)IND11 (2) (3)IMM01PD-(L)1(cHL) MDSCMML-cHLFLMZLINDCMCADCCTNBCNSCLCSLELNNMOSDPAH IMM01SIRPα-Fc IMM01CD47SIRPα-FcIgG1 FcIMM01—CD47/SIRPαFcγIMM01CD47(RBC)IMM01IMM01 o ◆20236IMM01II572024123126.0(95%CI23.5-28.3)51(ORR)64.7%33.3%(CR)15.7%(mCR+HI)3.9%HI11.8% mCR≥6ORR89.7%(26/29)CRR58.6% (17/29)(PFS)2025≥G3(TRAE) (≥10%)(78.9%)(66.7%)(66.7%)(57.9%)(45.6%)(17.5%)(12.3%)1(1.8%)3IMM01 ◆20245IMM01MDSIII(IMM01-009) ◆20235IMM01CMMLII242024123121.0(95%CI19.3–23.3)22ORR72.7%27.3% CR13.6% mCR4.5% HI27.3% mCR≥6ORR84.6% (11/13)CRR46.2% (6/13)(PFS)2025≥3TRAE (≥10%)(66.7%)(62.5%) (58.3%)(50.0%)(29.2%)(16.7%)IMM01CMMLIMM01CMML ◆202311IMM01CMML◆20246IMM01CMMLIII(IMM01-010)202411 o ◆2023119IMM01PD-1R/R cHLII202312II2024123133cHL R/R338CR15PRORR69.7%CRR24.2%TRAE ◆20241231IMM01 ◆20244IMM01PD-(L) 1cHLIII20247 oIMM2510 ◆20253IMM01IMM2510IND o ◆IMM01CD47/SIRPαIMM01IND 18A.08(3)IMM01 •IMM2510α(VEGFPD-L1) IMM2510—VEGFPD-L1VEGFPD-L1IMM2510TIMM2510FcADCC/ADCP o ◆20239IMM2510 I33RP2D20241231IMM2510 I202412313PR7SD415%IMM2510 ◆20241231Ib/II7460%VEGF- ◆20241224(Q2W)20 mg/kgIb/IITRAE12 o ◆202311IMM2510NSCLCTNBC IIIND202412NSCLC2025 oIMM27M ◆202310IMM2510IMM27MINDIMM2510–002R/RIMM2510+IMM27M Ib/II202472024723 IMM27M(CTLA-4 ADCC IMM27MCTLA-4ADCCCTLA-4TCD80/CD86TCTLA-4CTLA-4CD80/CD86T IMM27M IIMM27MRP2D20241231I2PR 20249(HR+)HER2 IMM0306α(CD47CD20) IMM0306αCD47CD20CD47CD20-IMM0306CD47ADCCIgG1 Fc(ADCP)(ADCC) o ◆20236IMM0306R/R CD20B-NHLIb/IIa ◆IMM0306R/R(FL)(MZL)Ib202412311.6 mg/kg2.0 mg/kg11Ib113CRFL7PR 5 FL2MZLORRCRR90.9%27.3%1.6 mg/kgIMM030620(RP2D)R/R FLMZL ◆20243IIa2024123136R/R FL2025 IMM0306Ib o ◆IMM0306B◆202410(SLE)II720252SLE ◆202412(NMOSD) Ib320252NMOSD◆202412(LN) IIIND◆FDAIND2025SLEIND IMM2520 (CD47PD-L1) IMM2520CD47PD-L1IMM2520ADCCIgG1 FcPD-L1NIMM01CD47CD47ADCCIgG1 FcADCPADCC 2023323IMM2520I0.1mg/kg202412312660.1mpk4mpk20241231PR10%SDPR IMM72/IMC-003 (ActRIIA) IMM72/IMC-003ActRIIAsotaterceptPAHIND20256IND IMM7220/IMC-010 (GLP-1ActRIIA) IMM7220/IMC-010ActRIIAGLP-1RFc IMM67 IMM67IMM67IMM67CMC2025 18A.08(3)IMM2510IMM27MIMM0306IMM2520IMM72/IMC-003IMM7220/IMC-010IMM67 202481Axion Bio, Inc.SynBioTx Inc.Instil Bio, Inc.(NASDAQTIL)InstilAxion Bio, Inc.IMM2510αIMM27M 15352127018 Instil2025AXN-2510/IMM2510NSCLC 2025 18A.08(3) 20242023123174.10.4Axion Bio, Inc.Axion Bio, Inc. 2023123118.22024123111.84.4 202312311.82024123111.53627.4(i)12.4(ii)1.7 CMC (i)CMCCROCDMOCMC(ii)(iii)(iv)(v)(vi)(vii) 20231231291.910.6%20241231322.8(i)CMC43.6IMM2510IMM0306CDMO(ii)20247.418.3(i)CRO4.0(ii)14.320241231 2023123180.419.4%2024123164.820241231 202312311.5202412313.4 202320241231 20231231379.520241231316.6 20241230100%98,188,983.55202411620241224101,078,891.81 2025214.075%25%14.34 28,763.10 (i) (ii) 2024123020252172025221 20241231752.120231231608.673.7 20241231867.9477.6274.535.620241231214.674.46.4100.9 20241231128.020231231367.6239.673.732.942.522.9 2024123137.920231231294.8 2024123120231231331.072.1258.991.9 3180.1 2024123126.4%2023123114.4%12.0%(i)55.4(ii)32.9 20241231115.42023123160.0202412312.95%3.60% 2023123114.82024123121.0 20241231202312316.0 20241231 20241231 2024123115620241231123.920231231155.720241231 202113120211220—— C.— 4. 202412312024930202411153,480,0002,120,00020231110202411151.5%4.5%20241231186,019,00047,914,000202412315%2024927 202412315% C.2.1 C.2.1(i)(ii)(iii) H 120,463,260HH202493HH202494120,463,260HH20249520245299394 20241025H14,114,006H2024